Case File
efta-02398723DOJ Data Set 11OtherEFTA02398723
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02398723
Pages
4
Persons
0
Integrity
Extracted Text (OCR)
EFTA DisclosureText extracted via OCR from the original document. May contain errors from the scanning process.
From:
Masha Drokova
Sent:
Friday, Novembeilli.
To:
jeffrey E.
Subject:
Re:
Because he worked with him.=Couldn't be totally objective :-)
Based on w=at I read/watched Thiel is equally smart
On N=v 2, 2017, at 9:53 PM, jeffrey E. <[email protected] <mailto:[email protected]=m» wrote:
Gates said no one smarter
On Fri, Nov 3, 2017 at 12:53 AM jeffrey E. <=a href="mailto:[email protected]">[email protected]>
wrote=
He is not an=investor type . He is s partner at a firm but used to be at Microsoft. = Just use him for
advice
<mailto:
On Thu, Nov 2, 2017 at 11:13 PM Masha Drokova <
wrote:
Thank=you for the comprehensive feedback Steven.
For me the main value is that the system=is an order of magnitude cheaper than existing
technologies, premised on le=eraging data to help users see what daily elements are affecting their bloo= sugar, and
predicting dangerous highs and lows before they happen so they c=n take actions beforehand. To date, their beta app
has lowered blood sugar averages in=over 55% of users 2x better than the world's most prescribed diabetes
drug,=Metformin. Which means that with the help of the date diabetes would need t= use less drugs. However I'd agree
on complexity of regulations and saturation on the m=rket.
I run Day One Ventures fund and=based in San Francisco. I'd be happy to connect in person
sometime to learn=about about your experience and tell about our investments and opportunitie= I see.
<mailto:
c=nnectivity.
On Nov 2, 2017, at 3:24=PM, Steven Sinofsky
» wrote:
Greetings Masha,
I apologi=e for the delay. I was at some events in in UK where I did not have
EFTA_R1_01433147
EFTA02398723
I have worked on a related portfolio c=mpany so I will have to be a bit abstract on the
specifics of this opportun=ty. So please excuse these brief thoughts. Also, the only information=l had was what was
provided in your mail which was limited relative to any d=tailed analysis.
* In general the challenge with g=ucose measurement is the finger prick. Any device
that relies on this will o=ly be marginally better than any other device, whether or not there is soft=are or a slightly more
convenient measuring device. This is a statement abo=t the inconvenience of a prick (and long term challenges) but also
the medi=al challenges on relying on that point in time.
* My sense is tha= going down the path of an innovation, that still has a prick, but
requires=a level of FDA approval is a difficult one to approach.
* This is=a very crowded space. There are a lot of apps, a lot of measuring devices, a=lot
of mixtures of app and measuring devices. It is very difficult to avoid=appearing as a commodity to consumers.
" While I understand there=is potential to see innovation using novel approaches to
analysis of data, i= is not clear to me how much better the approach can be for an individual w=th data.
* The real opportunity I might see is around measuring g=ucose or some related
telemetry to assist in compliance that is outside the=scope of a finger prick and measuring glucose directly. It seems like
we sh=uld have some other data point upon which to apply machine learning.
<=iv>
I hope this helps...any friend of JE is a friend of mine.=/div>
On Nov 1, 2017, at 4:43 PM, Masha Drokova <
w.=:ote:
Thank you J=ffrey. Steve, great meeting you.
Would appreciate your feed=ack
On Nov 1, 2017, at 9:31 AM, Jeffrey E. <
May be someone in your network who kno=s this area and can advise on this
kind of tech?
Center Health
Deck: https://dr=ve.google.com/file/d/0B5O93D3IJArEbXBsdll4elVob0U/view
<https://drive.=oogle.com/file/d/0BSO93D3UArEbXBsdll4elVob0U>
Our
memo:&n=sp;https://docs.google.com/documen=/d/1M7ZV7VEI8CTnb4EtYWFH2sq5dcCm0PM6g1AlcwrIOtM
<https://docs.google.com/document/d/1M72V7VEI8CTnb4EtYW=H2sq5dcCm0PM6g1AlcwrIOtM>
=div style="font•weight:normal">Center=nbsp;Health is building an Al-based
glucose monitoring system&nbs=;for the 1 in 11 Americans who suffer from diabetes, based on machine learn=ng and
their personalized Al, Aria. Users subscribe to their disposabl= test strips, a $148/yr US market, which are delivered
monthly, as Aria lea=ns about their diabetes and prompts behavioral changes to lower blood s=gar. The system is an
order of magnitude cheaper than existing technol=gies, premised on leveraging data to help users see what daily
elements are=nbsp;affecting their blood sugar, and predicting dangerous highs and lows b=fore they happen.
2
EFTA_R1_01433148
EFTA02398724
— Enormous pressure both from the industry players a=d companies such as
Apple and Google that try to develop non-invasive gluco=e monitoring that will wipe out test strip products
— H=rdware startup without a product to sell yet, finalizing the development
— Young team
=/blockquote>
please note
=he information contained in this communication is
confidential, may be a=torney-client privileged, may
constitute inside information, and is inte=ded only for
the use of the addressee. It is the property of
JEE
U=authorized use, disclosure or copying of this
communication or any part t=ereof is strictly prohibited
and may be unlawful. If you have received t=is
communication in error, please notify us immediately by
return e-m=il or by e-mail to [email protected]
<mailto:[email protected]> , and
destroy this communication and all copi=s thereof,
including all attachments. copyright -all rights reserved
=/div>
=/div>
=nbsp; please note
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitut= inside information, and is intended only for
the use of the addressee. 1= is the property of
JEE
Unauthorized use, disclosure or copying of th=s
communication or any part thereof is strictly prohibited
and may be=unlawful. If you have received this
communication in error, please notif= us immediately by
return e-mail or by e-mail to [email protected] <mailto:[email protected]> , and
destro= this communication and all copies thereof,
including all attachments. c=pyright -all rights reserved
=div dir="ltr">--
= please note
The information contained in this communication is
=onfidential, may be attorney-client privileged, may
constitute inside in=ormation, and is intended only for
3
EFTA_R1_01433149
EFTA02398725
the use of the addressee. It is the p=operty of
JEE
Unauthorized use, disclosure or copying of this
comm=nication or any part thereof is strictly prohibited
and may be unlawful.=If you have received this
communication in error, please notify us immed=ately by
return e-mail or by e-mail to [email protected] <mailto:jeevacation@gma=l.com> , and
destroy this com=unication and all copies thereof,
including all attachments. copyright -=11 rights reserved
4
EFTA_R1_01433150
EFTA02398726
Related Documents (6)
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.